MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

June 30, 2017

Conditions
Breast CancerHER2 Positive Breast Cancer
Interventions
DRUG

MM-302

DRUG

Gemcitabine

DRUG

Capecitabine

DRUG

Vinorelbine

DRUG

Trastuzumab

Trial Locations (109)

Unknown

Palo Verde Cancer Center, Glendale

Mayo Clinic Cancer Center, Scottsdale

University of Arizona Cancer Center, Tucson

St. Jude Heritage Healthcare, Fullerton

UC San Diego Moores Cancer Center, La Jolla

Ronald Reagan UCLA Medical Center, Los Angeles

Cancer Care Associates Medical Group, Redondo Beach

UCSF Medical Center, San Francisco

Sansum Clinic, Santa Barbara

Kaiser Permanent Medical Center, Vallejo

University of Colorado Cancer Center, Aurora

Rocky Mountain Cancer Centers, Littleton

Smilow Cancer Hospital at Yale New Haven Hospital, New Haven

Washington Cancer Institute, Washington D.C.

Florida Cancer Specialists & Research Institute, Fort Meyers

Memorial Regional Hospital, Hollywood

Mayo Clinic Cancer Center, Jacksonville

Sarah Cannon Research Institute, New Port Richey

UF Health Cancer Center at Orlando Health, Orlando

Florida Cancer Research Institute, Plantation

University of Miami Comprehensive Cancer Center, Plantation

Southeastern Regional Medical Center, Newnan

Northwestern University- Robert H. Lurie Comprehensive Cancer Center, Chicago

Rush University Medical Center, Chicago

University of Chicago, Chicago

Joliet Oncology-Hematology Associates, Joliet

Midwestern Regional Medical Center, Zion

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

McFarland Clinic PC, Ames

Johns Hopkins Medicine- The Sidney Kimmel Comprehensive Cancer Center, Baltimore

Dana-Farber Cancer Institute, Boston

St. Joseph Mercy Hospital, Ann Arbor

University of Michigan Health System, Ann Arbor

Minnesota Oncology Hematology, Coon Rapids

University of Minnesota- Masonic Cancer Center, Minneapolis

Mayo Clinic Cancer Center, Rochester

Saint Luke's Hospital, Kansas City

Barnes-Jewish West County Hospital, St Louis

Hackensack University Medical Center, Hackensack

New Mexico Cancer Care Alliance, Albuquerque

New York Oncology Hematology, P.C., Albany

North Shore Hematology Oncology Associates, East Setauket

Morton Coleman MD, New York

NYU Langone Medical Center, New York

Montefiore Medical Center, The Bronx

Office of Carey K. Anders, Chapel Hill

Duke Cancer Institute, Durham

Oncology Hematology Care, Cincinnati

Cleveland Clinic, Cleveland

Ohio State University Hospital, Columbus

St. Charles Health System, Bend

Magee-Womens Hospital of UPMC, Pittsburgh

Bon Secours Saint Francis Hospital Cancer Center, Greenville

Greenville Health System Cancer Institute, Greenville

Tennessee Oncology, Chattanooga

The Sarah Cannon Research Institute, Nashville

Vanderbilt University Medical Center, Nashville

Texas Oncology- Central Austin Cancer Center, Austin

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

Texas Oncology- Medical City, Dallas

Texas Oncology, El Paso

The Center for Cancer and Blood Disorders, Fort Worth

Texas Oncology-Houston Memorial City, Houston

The University of Texas- MD Anderson Cancer Center, Houston

Cancer Care Centers of South Texas, San Antonio

Texas Oncology, Tyler

Huntsman Cancer Institute, Salt Lake City

Virginia Oncology Associate, Norfolk

Swedish Medical Center, Issaquah

Northwest Medical Specialties, Tacoma

Medizinische Universitat Innsbruck, Innsbruck

AKh Allgemeines Krankenhaus der Stadt Linz, Linz

Medical University of Vienna, Vienna

GZA Ziekenhuizen - Campus Sint-Augustinus, Antwerp

University Hospital Antwerp, Antwerp

Cliniques Universitaires Saint-Luc, Brussels

Clinique Saint-Joseph, Liège

London Regional Cancer Center, London

Sunnybrook Health Sciences Centre, Toronto

University of Alberta- Cross Cancer Institute, Edmonton

McGill University Health Center, Québec

Motol University Hospital, Prague

Institut de Cancerologie de l'Ouest site Paul Papin, Angers

Centre Léon Bérard, Lyon

Hopital de l'Institut Curie, Paris

Institut de Cancerologie de l'Ouest, Saint-Herblain

Institut Claudius Regaud, Toulouse

Universitatsklinikum des Saarlandes, Homburg

Universitätsklinikum Schleswig-Holstein, Lübeck

Interdisziplinares Onkologisches Zentrum, Munich

Istituto Clinico Humanitas, Rozzano

Centro Riferimento Oncologico, IRCCS, Istituto Nazionale Tumori, Aviano

Azienda Ospedaliero-Universitaria di Bologna, Bologna

Azienda Socio Sanitaria Territoriale di Cremona, Cremina

Oncology Unit Macerata Hospital, Macerata

Istituto Europeo di Oncologia, Milan

Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Napoli

Instituto Oncologico Veneto IRCCS, Padua

Azienda Ospedaliero S. Maria di Terni, Terni

Hospital Universitario Vall d'Hebron, Barcelona

Hospital San Pedro de Alcantara, Cáceres

Hospital Universitario Reina Sofía, Córdoba

Hospital Universitario Arnau de Vilanova, Lleida

Hospital Clinico San Carlos, Madrid

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario Ramon y Cajal, Madrid

H.U.Son Espases, Palma de Mallorca

Hospital de Navarra, Pamplona

Hospital Universitario Virgen de la Macarena, Seville

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT02213744 - MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter